Insulet Corp.

PODD · NASDAQ · USD

Can Insulet fix retention in the first 90 days and keep growth near its long-term target while new tubeless pumps reach the pharmacy channel and pricing stops improving?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Adult diabetes market underpenetrated

    The bull case rests on a large group of people with diabetes who still inject insulin, so growth depends on converting them rather than taking share from other pumps.

  • Recurring pod reorders fund investment

    Each new patient becomes a stream of repeat pod orders, which is why the company can keep funding demand generation and a larger sales force while margins still expand.

  • Category expansion from new entrants

    Management argues new tubeless competitors advertise the category and pull more people off injections, so its volume can grow even as its share of tubeless pumps slips.

  • International markets still early

    Outside the United States the company is still entering new countries and adding sensor partners, a growth source that does not depend on fixing onboarding at home.

Bear case

  • Guidance cut and target review

    The company cut its United States outlook and put its long-range growth target under review, so the credibility of the next targets depends on evidence the fixes work.

  • Tubeless rivals reach pharmacy

    New tubeless pumps are reaching the same pharmacy channel, and while pricing has held so far, the company now plans next year on a flat price environment.

  • Cash spending on new plants

    Free cash flow is shrinking while the company builds factories in Malaysia and Costa Rica, which limits how much cash the growth converts into in the near term.

Bull and bear points

Growth & Execution

In short: Revenue growth is strong, but the U.S. outlook was cut after new patients dropped therapy sooner than planned.

Bull · 2

  • Type 2 automated delivery is used by under 5% of insulin users

    Management sizes about 2.5 million U.S. adults on basal-bolus insulin, so growth comes mainly from converting injections rather than winning share from other pumps.

    Q2 FY2026 call

  • International Omnipod grew above 40% for a third quarter

    Volume in the U.K., Germany and France plus newer launches in Canada, Australia and the Middle East lifted the full-year international outlook again this year.

    Q1 FY2026 call
Bear · 2

  • Management now expects lower type 2 retention than it guided

    A quarter earlier management described retention as very stable; it now says type 2 utilization and retention came in below plan and cut U.S. guidance to reflect those trends.

    Tone shiftQ1 FY2026 → Q2 FY2026

  • Growth is guided to exit 2026 in the mid-teens

    The fourth-quarter exit rate implied by guidance sits well below the target management set at Investor Day, and the long-range view will be revisited on the next call.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Gross margin stays high and profit per share grows, while free cash flow falls on factory spending.

Bull · 2

  • Gross margin held up as new plants ramped

    Productivity at Acton and Malaysia plus positive pricing offset the excess and obsolescence costs of switching pods to new sensor configurations this year.

    Q2 FY2026 call

  • Buyback authorization adds to earnings per share growth

    The board added $350 million in repurchase authorization, and the company deployed roughly the whole of it in the first quarter, so profit per share grows faster than total profit.

    Q4 FY2025 call
Bear · 2

  • Reported operating margin narrowed in the second quarter

    A medical device correction, excess and obsolescence charges from new pod configurations and a step-up in research spending weighed on profit even as revenue grew quickly.

    Filed financials

  • Free cash flow came in below the prior year

    Free cash flow of $294 million over the past year trailed the $405 million of the prior period as capital spending on new factories rose and the earlier figure included a one-time tax benefit.

    Filed financials

Market Position

In short: Omnipod is the most prescribed tubeless pump, but new tubeless rivals are reaching the same pharmacy channel.

Bull · 2

  • Pharmacy coverage reaches more than 90% of insured lives

    The company added coverage for another 6.5 million lives in the second quarter and removed prior authorization steps for roughly 10 million more.

    Q2 FY2026 call

  • Competitive conversions were the strongest since late 2023

    Switches from other automated systems added to new starts in the U.S. type 1 business, showing the pump holds its place with prescribers already using automation.

    Q3 FY2025 call
Bear · 2

  • Price guidance shifted from rising to slightly lower

    Management had told investors to expect positive U.S. pricing for three years; it now expects pricing to stay positive but at a lower level as competitors enter the pharmacy channel.

    Tone shiftQ1 FY2026 → Q2 FY2026

  • FDA updated its notice on the March device correction

    The agency republished its communication after the company's April update, which management said caused confusion, keeping device quality and regulatory risk in view for a high-volume disposable product.

    Q1 FY2026 call